A single masked trial of cyclosporin A 5 mg/ kg/day versus monthly 1 g intravenous boluses of cyclophosphamide was conducted among 23 patients with Behset's syndrome and active, potentially reversible uveitis. The trial was unmasked after a mean of 12 (SD 2) months for the cyclosporin A group (n= 12) and a mean of 10 (SD 3) months for the cyclophosphamide group (n=I1). During the initial 6 months the visual acuity significantly improved (p<0 001) in the cyclosporin A group whereas this was not observed in the cyclophosphamide group. The subsequent follow-up of patients up to 24 months suggested that the initial improvement in visual acuity with cyclosporin A was not sustained. More extensive and especially longterm studies of cyclosporin A in the uveitis of Beh4et's syndrome are warranted.

In this study, autologous serum testing was found to highly positive in chronic urticaria patients with HP IgG antibody, but the relationship between autoimmunity and HP infection requires further investigations.